UX007

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Glucose Transporter Type 1 Deficiency Syndrome

Conditions

Glucose Transporter Type 1 Deficiency Syndrome

Trial Timeline

Sep 10, 2015 → Oct 22, 2019

NCT ID

NCT02599961

About UX007

UX007 is a phase 2 stage product being developed by Ultragenyx Pharmaceutical for Glucose Transporter Type 1 Deficiency Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT02599961. Target conditions include Glucose Transporter Type 1 Deficiency Syndrome.

What happened to similar drugs?

4 of 6 similar drugs in Glucose Transporter Type 1 Deficiency Syndrome were approved

Approved (4) Terminated (3) Active (1)

✅Exenatide + MetforminEli LillyApproved

✅Candesartan + PlaceboAstraZenecaApproved

✅Sitagliptin-Metformin + Metformin + Placebo pillMerckApproved

✅cyclosporine micro-emulsionNovartisApproved

🔄Ramipril + RosiglitazonePfizerPhase 3

❌UX007 + PlaceboUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02599961	Phase 2	Terminated	Sep 10, 2015	Oct 22, 2019	Glucose Transporter Type 1 Deficiency Syndrome
NCT02214160	Phase 2	Completed	Dec 9, 2014	Dec 3, 2020	Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency
NCT01886378	Phase 2	Completed	Feb 6, 2014	Aug 25, 2016	Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Competing Products

17 competing products in Glucose Transporter Type 1 Deficiency Syndrome

See all competitors

Product	Company	Stage	Hype Score
Aspirin + Alpha lipoic acid + Olmesartan + Placebo	Daiichi Sankyo	Pre-clinical	26
Exenatide + Metformin	Eli Lilly	Approved	43
AZD1656	AstraZeneca	Phase 1	29
Candesartan + Placebo	AstraZeneca	Approved	35
Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg	Merck	Phase 2	35
Sitagliptin-Metformin + Metformin + Placebo pill	Merck	Approved	43
Comparator: exenatide + Comparator: exenatide + Comparator: Placebo	Merck	Phase 1	29
Placebo + Januvia	Merck	Phase 2	27
cyclosporine micro-emulsion	Novartis	Approved	35
Ramipril + Rosiglitazone	Pfizer	Phase 3	40
HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo	Haisco Pharmaceutical Group	Phase 2	35
Triheptanoin	Ultragenyx Pharmaceutical	Pre-clinical	20
UX007 + Placebo	Ultragenyx Pharmaceutical	Phase 3	26
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	25
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	29
UX007 + Placebo	Ultragenyx Pharmaceutical	Phase 2	29
GFT505 80mg + Placebo	Genfit	Phase 2	25